Market Closed -
Other stock markets
|
After market 11:20:00 am | |||
866.2 DKK | +0.41% | 866.4 | +0.02% |
Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
Apr. 15 | More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm | RE |
Evolution of the average Target Price on Novo Nordisk A/S
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Novo Nordisk A/S
BMO Capital | |
UBS | Jo Walton |
BARCLAYS | Emily Field |
alphavalue | Abhishek Raval |
BERENBERG | Kerry Holford |
DEUTSCHE BANK RESEARCH | Emmanuel Papadakis |
JPMORGAN | Richard Vosser |
JEFFERIES | Peter Welford |
Cantor Fitzgerald | |
DZ BANK | Elmar Kraus |
TD Cowen | |
Stifel Nicolaus | |
ODDO BHF | |
Berenberg Bank | |
CREDIT SUISSE | Lorenzo Biasio |
GOLDMAN SACHS | Keyur Parekh |
Morgan Stanley | |
BERNSTEIN RESEARCH | Wimal Kapadia |
BNP Paribas Exane | |
JPMorgan Chase | |
Guggenheim | |
Bryan, Garnier & Co. | |
Deutsche Bank Securities | |
DEUTSCHE BANK | Emmanuel Papadakis |
Liberum Capital | |
KEPLER CHEUVREUX | David Evans |
HSBC | Stephen McGarry |
INDEPENDENT RESEARCH | Tobias Gottschalt |
BANK OF AMERICA (BOFA) | Sachin Jain |
EPS Revisions
- Stock Market
- Equities
- NOVO B Stock
- Consensus Novo Nordisk A/S